Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−) advanced/metastatic breast cancer (ABC/MBC) in first line (1L), but little is known about their real-world use and clinical outc...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ruth Moulson, Guillaume Feugère, Tracy S. Moreira-Lucas, Florence Dequen, Jessica Weiss, Janet Smith, Christine Brezden-Masley
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2024-04-01
Series:	Current Oncology
Assuntos:	real-world evidence CDK4/6 inhibitors AI HR+ HER2− metastatic breast cancer
Acceso en liña:	https://www.mdpi.com/1718-7729/31/4/161
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!